vs
Side-by-side financial comparison of Amneal Pharmaceuticals, Inc. (AMRX) and Crescent Energy Co (CRGY). Click either name above to swap in a different company.
Crescent Energy Co is the larger business by last-quarter revenue ($865.0M vs $814.3M, roughly 1.1× Amneal Pharmaceuticals, Inc.). Amneal Pharmaceuticals, Inc. runs the higher net margin — 4.3% vs -1.0%, a 5.3% gap on every dollar of revenue. On growth, Amneal Pharmaceuticals, Inc. posted the faster year-over-year revenue change (11.5% vs -1.2%). Over the past eight quarters, Crescent Energy Co's revenue compounded faster (14.7% CAGR vs 11.1%).
Amneal Pharmaceuticals, Inc. is an American publicly traded pharmaceutical company that develops, manufactures and distributes generics and specialty pharmaceutical products. The company is headquartered in Bridgewater, New Jersey, and is one of the largest manufacturers of generic drugs in the United States.
Crescent Petroleum is the first and largest private upstream oil and gas company in the Middle East. Founded in 1971, Crescent Petroleum is headquartered in the Emirate of Sharjah, United Arab Emirates (UAE), with current operations in both the UAE and the Kurdistan Region of Iraq (KRI). As of 2023, Crescent Petroleum and the Iraqi Ministry of Oil have signed three twenty-year contracts as the company focus it efforts in aiding the redevelopment of Iraq.
AMRX vs CRGY — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $814.3M | $865.0M |
| Net Profit | $35.1M | $-8.7M |
| Gross Margin | 36.5% | — |
| Operating Margin | 13.8% | -6.2% |
| Net Margin | 4.3% | -1.0% |
| Revenue YoY | 11.5% | -1.2% |
| Net Profit YoY | 212.9% | 92.7% |
| EPS (diluted) | $0.10 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $814.3M | $865.0M | ||
| Q3 25 | $784.5M | $866.6M | ||
| Q2 25 | $724.5M | $898.0M | ||
| Q1 25 | $695.4M | $950.2M | ||
| Q4 24 | $730.5M | $875.3M | ||
| Q3 24 | $702.5M | $744.9M | ||
| Q2 24 | $701.8M | $653.3M | ||
| Q1 24 | $659.2M | $657.5M |
| Q4 25 | $35.1M | $-8.7M | ||
| Q3 25 | $2.4M | $-9.5M | ||
| Q2 25 | $22.4M | $153.2M | ||
| Q1 25 | $12.2M | $-2.1M | ||
| Q4 24 | $-31.1M | $-118.0M | ||
| Q3 24 | $-156.0K | $-9.9M | ||
| Q2 24 | $6.0M | $37.5M | ||
| Q1 24 | $-91.6M | $-24.2M |
| Q4 25 | 36.5% | — | ||
| Q3 25 | 34.9% | — | ||
| Q2 25 | 39.5% | — | ||
| Q1 25 | 36.8% | — | ||
| Q4 24 | 36.0% | — | ||
| Q3 24 | 38.4% | — | ||
| Q2 24 | 35.6% | — | ||
| Q1 24 | 36.1% | — |
| Q4 25 | 13.8% | -6.2% | ||
| Q3 25 | 9.0% | 3.6% | ||
| Q2 25 | 15.4% | 8.9% | ||
| Q1 25 | 14.4% | 18.1% | ||
| Q4 24 | 10.4% | -3.1% | ||
| Q3 24 | 12.6% | -1.0% | ||
| Q2 24 | 13.6% | 18.3% | ||
| Q1 24 | -1.6% | 20.4% |
| Q4 25 | 4.3% | -1.0% | ||
| Q3 25 | 0.3% | -1.1% | ||
| Q2 25 | 3.1% | 17.1% | ||
| Q1 25 | 1.8% | -0.2% | ||
| Q4 24 | -4.3% | -13.5% | ||
| Q3 24 | -0.0% | -1.3% | ||
| Q2 24 | 0.9% | 5.7% | ||
| Q1 24 | -13.9% | -3.7% |
| Q4 25 | $0.10 | — | ||
| Q3 25 | $0.01 | — | ||
| Q2 25 | $0.07 | — | ||
| Q1 25 | $0.04 | — | ||
| Q4 24 | $-0.10 | — | ||
| Q3 24 | $0.00 | — | ||
| Q2 24 | $0.02 | — | ||
| Q1 24 | $-0.30 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $282.0M | $10.2M |
| Total DebtLower is stronger | $2.6B | $5.5B |
| Stockholders' EquityBook value | $-70.8M | $5.2B |
| Total Assets | $3.7B | $12.4B |
| Debt / EquityLower = less leverage | — | 1.07× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $282.0M | $10.2M | ||
| Q3 25 | $201.2M | $3.5M | ||
| Q2 25 | $71.5M | $3.1M | ||
| Q1 25 | $59.2M | $6.3M | ||
| Q4 24 | $110.6M | $132.8M | ||
| Q3 24 | $74.0M | $136.2M | ||
| Q2 24 | $43.8M | $778.1M | ||
| Q1 24 | $46.5M | $5.3M |
| Q4 25 | $2.6B | $5.5B | ||
| Q3 25 | $2.6B | $3.2B | ||
| Q2 25 | $2.2B | $3.4B | ||
| Q1 25 | $2.2B | $3.6B | ||
| Q4 24 | $2.4B | $3.0B | ||
| Q3 24 | $2.4B | $3.2B | ||
| Q2 24 | $2.4B | $2.4B | ||
| Q1 24 | $2.4B | $1.7B |
| Q4 25 | $-70.8M | $5.2B | ||
| Q3 25 | $-109.5M | $4.5B | ||
| Q2 25 | $-112.1M | $4.5B | ||
| Q1 25 | $-131.7M | $3.3B | ||
| Q4 24 | $-109.3M | $3.1B | ||
| Q3 24 | $-93.4M | $2.9B | ||
| Q2 24 | $-57.5M | $2.1B | ||
| Q1 24 | $-63.7M | $2.0B |
| Q4 25 | $3.7B | $12.4B | ||
| Q3 25 | $3.6B | $9.7B | ||
| Q2 25 | $3.4B | $9.9B | ||
| Q1 25 | $3.4B | $9.9B | ||
| Q4 24 | $3.5B | $9.2B | ||
| Q3 24 | $3.5B | $9.3B | ||
| Q2 24 | $3.5B | $7.5B | ||
| Q1 24 | $3.5B | $6.8B |
| Q4 25 | — | 1.07× | ||
| Q3 25 | — | 0.72× | ||
| Q2 25 | — | 0.75× | ||
| Q1 25 | — | 1.10× | ||
| Q4 24 | — | 0.97× | ||
| Q3 24 | — | 1.12× | ||
| Q2 24 | — | 1.12× | ||
| Q1 24 | — | 0.88× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $130.3M | $371.0M |
| Free Cash FlowOCF − Capex | $108.5M | — |
| FCF MarginFCF / Revenue | 13.3% | — |
| Capex IntensityCapex / Revenue | 2.7% | — |
| Cash ConversionOCF / Net Profit | 3.72× | — |
| TTM Free Cash FlowTrailing 4 quarters | $269.9M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $130.3M | $371.0M | ||
| Q3 25 | $118.5M | $473.1M | ||
| Q2 25 | $83.8M | $499.0M | ||
| Q1 25 | $7.4M | $337.1M | ||
| Q4 24 | $118.1M | $384.4M | ||
| Q3 24 | $141.8M | $368.0M | ||
| Q2 24 | $39.7M | $286.9M | ||
| Q1 24 | $-4.4M | $183.8M |
| Q4 25 | $108.5M | — | ||
| Q3 25 | $106.2M | — | ||
| Q2 25 | $61.0M | — | ||
| Q1 25 | $-5.8M | — | ||
| Q4 24 | $102.9M | — | ||
| Q3 24 | $124.8M | — | ||
| Q2 24 | $29.0M | — | ||
| Q1 24 | $-13.6M | — |
| Q4 25 | 13.3% | — | ||
| Q3 25 | 13.5% | — | ||
| Q2 25 | 8.4% | — | ||
| Q1 25 | -0.8% | — | ||
| Q4 24 | 14.1% | — | ||
| Q3 24 | 17.8% | — | ||
| Q2 24 | 4.1% | — | ||
| Q1 24 | -2.1% | — |
| Q4 25 | 2.7% | — | ||
| Q3 25 | 1.6% | — | ||
| Q2 25 | 3.2% | — | ||
| Q1 25 | 1.9% | — | ||
| Q4 24 | 2.1% | — | ||
| Q3 24 | 2.4% | — | ||
| Q2 24 | 1.5% | — | ||
| Q1 24 | 1.4% | — |
| Q4 25 | 3.72× | — | ||
| Q3 25 | 50.00× | — | ||
| Q2 25 | 3.74× | 3.26× | ||
| Q1 25 | 0.61× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 6.62× | 7.64× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMRX
| Oral Solid | $188.7M | 23% |
| Distribution Service | $107.7M | 13% |
| Central Nervous System | $104.8M | 13% |
| Government Label | $86.8M | 11% |
| Other Dosage Forms | $68.2M | 8% |
| Transdermal | $56.1M | 7% |
| Hormonal Allergy | $47.6M | 6% |
| Ephinephrine Auto Injector | $39.1M | 5% |
| Injectable | $37.4M | 5% |
| Other | $33.6M | 4% |
| Biosimilar | $29.4M | 4% |
| Selling General And Administrative Expenses | $14.9M | 2% |
CRGY
| Oil Reserves | $554.3M | 64% |
| Natural Gas Production | $182.6M | 21% |
| Natural Gas Liquids Reserves | $92.3M | 11% |
| Midstream And Other | $35.8M | 4% |
